title: Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.
authors.forename: S C B
authors.initials: SC
authors.lastname: Teoh
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: A
authors.initials: A
authors.lastname: Hogan
authors.forename: R
authors.initials: R
authors.lastname: Lee
authors.forename: A V
authors.initials: AV
authors.lastname: Ramanan
authors.forename: A D
authors.initials: AD
authors.lastname: Dick
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D000068800:Etanercept; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013577:Syndrome; D015866:Uveitis, Posterior / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D011239:Prednisolone; D000068800:Etanercept; D008775:Methylprednisolone; D008727:Methotrexate